? OVERALL The Duke Comprehensive Cancer Center was founded as a matrix center within the Duke University School of Medicine in 1972 and the Duke Cancer Institute (DCI) was created as a new administrative entity within Duke Health in October 2010, with authority and responsibility for all cancer-related activities at Duke University and in the Duke University Health System. The DCI was started with significant investments from Duke Health, including a new $243M clinical care outpatient facility, over $60 million of new funds available to support new initiatives, and a commitment for ongoing annual investment by the Duke Health System. DCI faculty include well-established and funded experts spanning the full spectrum of cancer research fields, from intracellular signaling to cancer genomics to therapeutic development and testing to population science. DCI programmatic activities support the career development of the next generation of cancer experts and provide platforms for multi-disciplinary scientific teams to develop and test new hypotheses. During the most recent funding period, the DCI structure has continued to evolve and mature, currently consisting of 304 members from 34 departments within 7 schools at Duke University (Medicine, Nursing, Arts and Sciences, Engineering, Public Policy, Environment, and Business) and organized as 8 multi-disciplinary research programs (2 basic discovery, 1 population science, and 5 translational/clinical) whose work is supported by 14 Shared Resources (8 lab-based and 6 supporting translational/clinical/population research activities). In addition to Program and Shared Resource leaders, DCI senior leadership, which includes an Executive Director, Deputy Director, 7 Associate Directors, and 8 other key leaders, provides oversight and direction of DCI initiatives. DCI members are currently supported by over $111M of external cancer-related grant support (direct costs), over $63M of which is peer- reviewed, including 32 peer-reviewed, multi-investigator grants (involving 81 subprojects/cores) and 61 training and fellowship awards. DCI members published over 5,750 cancer-focused papers during the past funding period, ~40% of which represent collaborative efforts between DCI investigators. On average, ~7,000 new cancer patients are seen each year at the Duke University Hospital. In 2018, DCI Programs enrolled over 4,000 patients on clinical trials, including nearly 2,000 interventional accruals and 770 therapeutic accruals. DCI is heavily engaged in both community outreach/engagement and educating the next generation of cancer clinicians and scientists. Duke Health support of the DCI included a total of over $65M of additional investment in the most recent funding period, including support for recruitment, retention, and protected academic time for DCI faculty. The DCI completed an extensive 5-year Strategic Planning process, identifying strategic goals and priorities that enable the DCI mission to ?Discover, Develop, and Deliver the future of cancer care?now?, resulting in a series of discrete recommendations that are serving as a guide for determining current and future resource allocation, recruiting priorities, and infrastructure changes required to achieve DCI goals.

Public Health Relevance

(RELEVANCE STATEMENT) ? OVERALL The Duke Cancer Institute, which has authority and responsibility for all cancer-related activities at Duke University and in the Duke University Health System, provides support and promotes collaborations between faculty and staff involved in cancer research, education, and patient care. This Cancer Center Support Grant facilitates oversight and integration of all cancer-related research activities, from basic research to translational studies to clinical and population investigation to community outreach to global cancer. Building upon an extensive strategic planning process, priority activities to maximize local, regional, and national impact have been identified.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
He, Min
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Duke University
Schools of Medicine
United States
Zip Code
Duan, Bensong; Hu, Jiangfeng; Liu, Hongliang et al. (2018) Genetic variants in the platelet-derived growth factor subunit B gene associated with pancreatic cancer risk. Int J Cancer 142:1322-1331
Wu, Mengxi; Huang, Po-Hsun; Zhang, Rui et al. (2018) Circulating Tumor Cell Phenotyping via High-Throughput Acoustic Separation. Small 14:e1801131
Vlahovic, Gordana; Meadows, Kellen L; Hatch, Ace J et al. (2018) A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. Oncologist 23:782-790
Xu, Yinghui; Liu, Hongliang; Liu, Shun et al. (2018) Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. Int J Cancer 143:2400-2408
Feng, Yun; Wang, Yanru; Liu, Hongliang et al. (2018) Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. Mol Carcinog 57:216-224
Naqvi, Ibtehaj; Gunaratne, Ruwan; McDade, Jessica E et al. (2018) Polymer-Mediated Inhibition of Pro-invasive Nucleic Acid DAMPs and Microvesicles Limits Pancreatic Cancer Metastasis. Mol Ther 26:1020-1031
Wen, Juyi; Liu, Hongliang; Wang, Lili et al. (2018) Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. J Thorac Oncol 13:660-675
Li, Bo; Wang, Yanru; Xu, Yinghui et al. (2018) Genetic variants in RORA and DNMT1 associated with cutaneous melanoma survival. Int J Cancer 142:2303-2312
Gearhart-Serna, Larisa M; Jayasundara, Nishad; Tacam Jr, Moises et al. (2018) Assessing Cancer Risk Associated with Aquatic Polycyclic Aromatic Hydrocarbon Pollution Reveals Dietary Routes of Exposure and Vulnerable Populations. J Environ Public Health 2018:5610462
Bakthavatsalam, Subha; Sleeper, Mark L; Dharani, Azim et al. (2018) Leveraging ?-Glutamyl Transferase To Direct Cytotoxicity of Copper Dithiocarbamates against Prostate Cancer Cells. Angew Chem Int Ed Engl 57:12780-12784

Showing the most recent 10 out of 513 publications